Journal of Affective Disorders
Volume 121, Issue 1 , Pages 143-146, February 2010

Onset-age of bipolar disorders at six international sites

  • R.J. Baldessarini

      Affiliations

    • Department of Psychiatry & Neuroscience Program, Harvard Medical School, USA
    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Corresponding Author InformationCorresponding author. Mailman Research Center, McLean Hospital, 115 Mill Street, Belmont, MA 02478-9106, USA.
  • ,
  • L. Bolzani

      Affiliations

    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Department of Psychiatry, Viarnetto Psychiatric Clinic, Lugano, Switzerland
    • Department of Psychiatry, University of Cagliari; Lucio Bini Mood Disorder Center, Cagliari, Sardinia, Italy
  • ,
  • N. Cruz

      Affiliations

    • Department of Psychiatry & Neuroscience Program, Harvard Medical School, USA
    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Bipolar Disorders Program, Institute of Clinical Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Spain
  • ,
  • P.B. Jones

      Affiliations

    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Bipolar Disorders Program, Institute of Clinical Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Spain
  • ,
  • M. Lai

      Affiliations

    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Department of Psychiatry, Viarnetto Psychiatric Clinic, Lugano, Switzerland
    • Department of Psychiatry, University of Cagliari; Lucio Bini Mood Disorder Center, Cagliari, Sardinia, Italy
  • ,
  • B. Lepri

      Affiliations

    • Department of Psychiatry, Viarnetto Psychiatric Clinic, Lugano, Switzerland
    • Department of Psychiatry, University of Cagliari; Lucio Bini Mood Disorder Center, Cagliari, Sardinia, Italy
  • ,
  • J. Perez

      Affiliations

    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • CAMEO Early Intervention Services, Department of Psychiatry, University of Cambridge, UK
  • ,
  • P. Salvatore

      Affiliations

    • Department of Psychiatry & Neuroscience Program, Harvard Medical School, USA
    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Department of Neuroscience, Section of Psychiatry, University of Parma, Italy
  • ,
  • M. Tohen

      Affiliations

    • Department of Psychiatry & Neuroscience Program, Harvard Medical School, USA
    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Department of Psychiatry, University of Texas, San Antonio, TX, United States
  • ,
  • L. Tondo

      Affiliations

    • Department of Psychiatry & Neuroscience Program, Harvard Medical School, USA
    • Department of Psychiatry, Viarnetto Psychiatric Clinic, Lugano, Switzerland
    • Department of Psychiatry, University of Cagliari; Lucio Bini Mood Disorder Center, Cagliari, Sardinia, Italy
  • ,
  • E. Vieta

      Affiliations

    • International Consortium for Bipolar Disorder Research, McLean Division of Massachusetts General Hospital, Belmont, MA, USA
    • Bipolar Disorders Program, Institute of Clinical Neuroscience, Hospital Clinic, IDIBAPS, CIBERSAM, University of Barcelona, Spain

Received 6 February 2009; received in revised form 27 May 2009; accepted 28 May 2009.

Abstract 

Background

Onset-age is a stable characteristic of bipolar disorder (BPD) patients of clinical and probable psychobiological importance, but large pooled clinical samples from multiple sites employing modern diagnostic criteria to quantify onset-age remain rare.

Methods

We pooled diagnostic, demographic, and clinical data from 1566 BPD patients from six international sites (5 European, 1 US) to compare onset-ages in subgroups.

Results

Median±IQR onset in 1090 BP-I patients was 5.8 years younger than 476 BP-II cases (24.3±18.3 vs. 30.1±13.8 years; p<0.0001). Onset-age ranked: [a] BP-I men (23.0±12.8); [b] BP-I women (26.0±14.2); [c] BP-II men (29.7±19.1); and [d] BP-II women (30.1±17.5 years. Juvenile-onset (≤age 20) was more common in Europe than the US (27% vs. 16%), as was childhood-onset (<13 years: 3.3% vs. 0%; both p<0.001). Proportion of all cases, and median onset for first episodes ranked: [a] BP-I psychotic (6.3%; 22.7±9.2); [b] BP-I manic (29.3%; 24.0±12.1); [c] BP-I depressed (25.1%; 24.5±14.9); [d] BP-I mixed (9.7%; 27.9±16.0); [e] BP-II depressed (26.9%; 30.0±19.5); and [f] BP-II hypomanic (2.8%; 33.6±15.1 years; p<0.0001). Among BP-I patients, onset was similar for various forms of mania and major depression; in BP-II patients initial depression was 9.6-times more frequent and diagnosed earlier than hypomania.

Limitations

There was some variance among sites and only 34.1% of patients were evaluated at onset.

Conclusions

Type I BPD began much earlier than type II; its mainly psychotic presentations occurred earliest, but BP-I men were younger than women, especially at psychotic or mixed onsets.

Keywords: Bipolar I and II disorders, Onset-age

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Disclosures: Dr. Baldessarini has recently been a consultant or investigator-initiated research collaborator with: AstraZeneca, Auritec, Biotrofix, Janssen, JDS-Noven, Lilly, Luitpold, NeuroHealing, Novartis, Pfizer, and SK-BioPharmaceutical Corporation; he is not a member of pharmaceutical speakers' bureaus, nor does he or any family member hold equity positions in biomedical or pharmaceutical corporations. Dr. Perez is a former employee of Eli Lilly Corporation (to 2004). Dr. Tohen was an employee of Eli Lilly & Co (to 2008), and is a consultant or has received speaker's honoraria from Astra-Zeneca, BristolMyers-Squibb, Eli Lilly, Glaxo-SmithKline, Johnson & Johnson and Wyeth Corporations; his spouse is an Eli Lilly employee and stockholder. Dr. Vieta has served as a consultant or speaker for Astra-Zeneca, BristolMyers-Squibb, Eli Lilly, Forest Research Institute, Glaxo-Smith-Kline, Janssen-Cilag, Jazz, Lundbeck, Merck, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Servier, Shering-Plough, United Biosource, and Wyeth Corporations. Other authors have no relevant disclosures of potential conflicts of interest.

PII: S0165-0327(09)00253-5

doi:10.1016/j.jad.2009.05.030

Journal of Affective Disorders
Volume 121, Issue 1 , Pages 143-146, February 2010